Image

Global Retinal Disease Therapeutics Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Retinal Disease Therapeutics Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Sep 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Retinal Disease Therapeutics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 12.57 USD Billion
Diagram Market Size (Forecast Year) USD 25.69 USD Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Retinal Disease Therapeutics Market, By Disorder (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters), Disorder Type (Genetic, Age Related), Treatment Techniques (Laser, Freezing, Implanting, Indenting, Pneumatic Retinopexy, Scleral Buckling, Vitrectomy), Route of Administration (Oral, Topical, Intravitreal, Others), End-Users (Hospitals, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2030.

Retinal Disease Therapeutics Market

Retinal Disease Therapeutics Market Analysis and Size

The retina is a delicate layer of tissue located at the back end of the eyes and is responsible for light sensing and transferring images to brain, any form of retinal disorder may damage this delicate tissue and affect vision and in serious cases lead to blindness. Retinal disorders may be genetic or age-related, causing degenerative changes in vision. A retinal examination is however the first step in diagnosis of the potential disease along with genetic testing for genetic retinal disorders.

Retinal disorders have both high prevalence and incidence in the geriatric population and diabetic patients, therefore rise in both adult and diabetic patient population will boost the retinal disease therapeutics market.

Data Bridge Market Research analyses that the retinal disease therapeutics market which was USD 12.57 billion in 2022, would reach up to USD 25.69 billion by 2030, and is expected to undergo a CAGR of 9.3% during the forecast period. “Macular degeneration” dominates the disorder segment of the retinal disease therapeutics market owing to the higher prevalence. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Retinal Disease Therapeutics Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Disorder (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters), Disorder Type (Genetic, Age Related), Treatment Techniques (Laser, Freezing, Implanting, Indenting, Pneumatic Retinopexy, Scleral (SKLAIR-ul) Buckling, Vitrectomy), Route of Administration (Oral, Topical, Intravitreal, Others), End-Users (Hospitals, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Santen Pharmaceutical Co. Ltd. (Japan), Bausch Health Companies Inc. (Canada), Sentis Pharma Pvt Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Abbvie (U.S.), Regeneron Pharmaceuticals, Inc. (U.S.), Akorn (U.S.), Mitotech, SA (Russia), Kubota Pharmaceutical Holdings Co., Ltd. (Japan), GRAYBUG VISION, INC. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Otsuka Pharmaceutical Co Ltd. (Japan), Senju Pharmaceutical Co., Ltd. (Japan), Valent Pharmaceuticals North America LLC (U.S.), Genentech, Inc. (U.S.), Ocular Therapeutix (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Kala Pharmaceuticals (U.S.), Eyevensys (France) and Aldeyra Therapeutics, Inc. (U.S.)

Market Opportunities

  • Medical research and development
  • Technological advancements

Market Definition

Retinal diseases are a group of medical conditions that affect the retina, which is the light-sensitive tissue located at the back of the eye. These diseases can disrupt the normal functioning of the retina, leading to vision impairment or even blindness. Common retinal diseases include macular degeneration, diabetic retinopathy, retinal detachment, retinitis pigmentosa, and others. Therapeutics for retinal diseases aim to manage and treat these conditions to preserve or improve a patient's vision. Treatment approaches can vary depending on the specific disease and its severity but may include medications, laser therapy, surgery, and implantable devices among others.

Retinal Disease Therapeutics Market Dynamics

Drivers

  • Aging Population

The aging population is more susceptible to retinal diseases, such as age-related macular degeneration (AMD). As the global population continues to age, the prevalence of retinal diseases is expected to increase, driving the demand for therapeutics

  • Rising Incidence of Diabetes

Diabetic retinopathy is a common retinal disease associated with diabetes. The increasing incidence of diabetes worldwide is a significant driver of the retinal disease therapeutics market

Opportunities

  • Medical Research and Development

Increased demand for retinal disease treatments will drive research and development efforts. This presents opportunities for pharmaceutical and biotech companies to innovate and develop new drugs and therapies for retinal diseases

  • Technological Advancements

As the market grows, there will be a greater need for advanced diagnostic and treatment technologies. This creates opportunities for companies involved in developing cutting-edge medical devices and imaging technologies for retinal diseases

Restraints/Challenges

  • High Cost of Treatment

The cost of some retinal disease treatments, including anti-VEGF drugs and surgical interventions, can be prohibitively expensive. This cost burden can limit access to these therapies for some patients

  • Limited Efficacy of Current Treatments

While significant progress has been made, some retinal diseases still lack highly effective treatments. For instance, advanced stages of certain diseases such as retinitis pigmentosa may have limited therapeutic options

This retinal disease therapeutics Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Retinal disease therapeutics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Development

  • In October 2022, in a 600% million deal, Boehringer Ingelheim targets Surrozen’s preclinical disease asset. Surrozen has caught the attention of Boehringer Ingelheim, which paid the California biotech USD 12.5 million upfront for its preclinical asset designed to regenerate healthy eye tissue and potentially reverse retinal disease

Global Retinal Disease Therapeutics Market Scope

The retinal disease therapeutics Market is segmented on the basis of disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disorder

  • Macular Degeneration
  • Diabetic Eye Disease
  • Retinal Detachment
  • Retinoblastoma
  • Macular Pucker
  • Macular Hole
  • Floaters

Disorder Type

  • Genetic
  • Age Related

Treatment Techniques

  • Laser
  • Freezing
  • Implanting
  • Indenting
  • Pneumatic Retinopexy
  • Scleral Buckling
  • Vitrectomy

Route of Administration

  • Oral
  • Topical
  • Intravitreal
  • Others

End-Users

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Global Retinal Disease Therapeutics Market Regional Analysis/Insights

The retinal disease therapeutics market is analyzed and market size insights and trends are provided by disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel as referenced above.

The countries covered in the retinal disease therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America accounts for the largest market share due to the high healthcare expenditure and good quality medical facilities along with the majority of population have insurance cover to claim this type of expensive treatment.

Asia-Pacific region is expected to record the fastest growth during the forecast period due to increasing patient pool, improving public and private reimbursement infrastructure, and constant development of healthcare facilities.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Retinal Disease Therapeutics Market Share Analysis

The retinal disease therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to retinal disease therapeutics market.

Some of the major players operating in the retinal disease therapeutics market are:

  • Santen Pharmaceutical Co. Ltd. (Japan)
  • Bausch Health Companies Inc. (Canada)
  • Sentis Pharma Pvt Ltd. (India)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Abbvie (U.S.)
  • Regeneron Pharmaceuticals, Inc. (U.S.)
  • Akorn (U.S.)
  • Mitotech, SA (Russia)
  • Kubota Pharmaceutical Holdings Co., Ltd. (Japan)
  • GRAYBUG VISION, INC. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Otsuka Pharmaceutical Co Ltd. (Japan)
  • Senju Pharmaceutical Co., Ltd. (Japan)
  • Valent Pharmaceuticals North America LLC (U.S.)
  • Genentech, Inc. (U.S.)
  • Ocular Therapeutix (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Kala Pharmaceuticals (U.S.)
  • Eyevensys (France)
  • Aldeyra Therapeutics, Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Retinal Disease Therapeutics Market will be worth USD 25.69 billion by 2030.
The Retinal Disease Therapeutics Market growth rate is 9.3% during the forecast.
The Rising Incidence of Diabetes & Aging Population are the growth drivers of the Retinal Disease Therapeutics Market.
The disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel are the factors on which the Retinal Disease Therapeutics Market research is based.
Surrozen has caught the attention of Boehringer Ingelheim, which paid the California biotech USD 12.5 million upfront for its preclinical asset designed to regenerate healthy eye tissue and potentially reverse retinal disease & Boehringer Ingelheim targets Surrozen’s preclinical disease asset are the latest developments in the Retinal Disease Therapeutics Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials